Connection

Xinghuan Wang to Immunogenicity, Vaccine

Back to Details
This is a "connection" page, showing publications Xinghuan Wang has written about Immunogenicity, Vaccine.
Xinghuan Wang
Connection Strength
0.019
Immunogenicity, Vaccine
  1. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021 12; 21(12):1654-1664.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.